RSV Epidemiology and Molecular Diversity study version 2.0

  • Research type

    Research Study

  • Full title

    RSV Epidemiology and Molecular Diversity - a pilot study in NW London during the 2021/2022 RSV season

  • IRAS ID

    298527

  • Contact name

    Paul Randell

  • Contact email

    paulrandell@nhs.net

  • Sponsor organisation

    Imperial College

  • Duration of Study in the UK

    0 years, 6 months, 0 days

  • Research summary

    Respiratory Syncytial Virus (RSV) is a leading cause of acute respiratory tract infections in infants and causes significant numbers of hospital admissions and deaths globally every year. Prevention of RSV is a major global priority but despite more than 50 years of research there is no safe and effective vaccine. The successful introduction of newer therapeutics or vaccines requires an understanding of the epidemiology and viral diversity that may impact the efficacy of these agents. Despite all that is known about RSV there is still a paucity in the understanding of RSV epidemiology.

    This pilot study aims to describe the epidemiology of patients testing positive in NW London during the 2021/2022 RSV season. While the burden of disease is primarily in the paediatric patient group, the data from adults and children with be investigated to gain greater understanding of the local RSV transmission dynamics and molecular diversity of the virus.

  • REC name

    North West - Haydock Research Ethics Committee

  • REC reference

    22/NW/0165

  • Date of REC Opinion

    16 Jun 2022

  • REC opinion

    Further Information Favourable Opinion